Study to Evaluate Diphenhydramine in Children and Adolescents

• ClinicalTrials.gov Identifier: NCT00762749
• Recruitment Status: Completed
• First Posted: September 30, 2008
• Last Update Posted: October 6, 2011
• Sponsor: Johnson & Johnson Consumer and Personal Products Worldwide
• Information provided by (Responsible Party): Johnson & Johnson Consumer and Personal Products Worldwide

Study Description

Brief Summary:

To characterize the pharmacokinetics of diphenhydramine in two pediatric populations: children, ages 2 to < 12 years, and adolescents, ages 12 to < 18 years.

Condition or disease	Intervention/treatment	Phase
Allergic Rhinitis	Drug: diphenhydramine HCl	Phase 1

Detailed Description:

This study has an open-label, single-dose classical pharmacokinetic design with no comparator treatment or group. Twenty-four (24) children, ages 2 to < 12 years, and 12 adolescents, ages 12 to < 18 years, with symptoms due to hay fever or other upper respiratory allergies will complete the study. To ensure that younger children are represented, at least 35% (8) of the children enrolled will range from 2 to < 6 years of age.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 36 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: An Open-Label, Single-Dose Study Evaluating the Pharmacokinetics of Diphenhydramine in Children and Adolescents
• Study Start Date: September 2008
• Actual Primary Completion Date: November 2008
• Actual Study Completion Date: November 2008

Arms and Interventions

Arm	Intervention/treatment
Experimental: diphenhydramine HCl; diphenhydramine HCl / Children's Benadryl Allergy Liquid	Drug: diphenhydramine HCl; A single liquid dose of diphenhydramine HCl (12.5 mg /5 mL) followed by water, according to an age-weight dosing schedule; Other Name: Children's Benadryl Allergy Liquid

Outcome Measures

Primary Outcome Measures :

1. Pharmacokinetic parameters [ Time Frame: predose (0), and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, and 24 hours after the dose ]

Secondary Outcome Measures :

1. Safety Assessments will consist of monitoring vital signs and all non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs), their frequency, severity, seriousness, and relationship to the investigational product. [ Time Frame: throughout duration of the study + 2 days (+ 30 days for spontaneously reported SAEs) ]

Eligibility Criteria

• Ages Eligible for Study: 2 Years to 17 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male and female children and adolescents, ages 2 to < 18 years, with a minimum weight of 24 pounds will be eligible to participate. In addition, each subject will be > 5th percentile and < 95th percentile for weight based on age and gender.
• Subjects will have a body mass index (BMI) > 5th percentile and less than or equal to 90th percentile for age and gender.
• Subjects who have a history of allergic rhinitis and who are experiencing symptoms due to hay fever or other upper respiratory allergies will be included.
• Subjects who do not use concurrent medications, except for low-dose inhaled glucocorticosteroids for allergic rhinitis or mild concurrent asthma, if dose is stabilized before entry in the study (ie, dose is not changed for 1 month prior to entry or during the study), and inhaled short-acting beta-2 adrenergic agonists for concomitant asthma, as needed;

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurologic disease.
• Findings from the medical history or physical examination with vital sign measurements that are not within the range of clinical acceptability.
• Have a known sensitivity or allergy to diphenhydramine or EMLA cream.
• Have a known sensitivity or allergy to red dye.
• Have asthma symptoms at the time of study entry or requiring medications other than allowed in Inclusion Criterion 4;
• Took any prescription (other than allowed in Inclusion Criterion 4) or nonprescription medication, within seven days or five half-lives (whichever is longer) before the study's start date.
• Took any herbal supplements or drank grapefruit juice with 28 days of the study's start date.
• Participated in, or completed, another clinical trial within seven weeks before the study's start date.
• Have a history of drug, alcohol, and tobacco use (older children and adolescents)
• Have a history of hepatitis B, a previous positive test for hepatitis B surface antigen, or a previous positive hepatitis C antibody.
• Have a history of HIV infection or previous demonstration of HIV antibodies.
• Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception from at least three months prior to the first dose of study medication until completion of follow-up procedures.

Contacts and Locations

Locations

United States, Arkansas

Arkansas Medical Research Testing Center

Little Rock, Arkansas, United States, 72202

Sponsors and Collaborators

Johnson & Johnson Consumer and Personal Products Worldwide

Investigators

• Study Director: Cathy M Gelotte, PhD; McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.

More Information

• Responsible Party: Johnson & Johnson Consumer and Personal Products Worldwide
• ClinicalTrials.gov Identifier: NCT00762749
• Other Study ID Numbers: DPHNCO1003
• First Posted: September 30, 2008
• Last Update Posted: October 6, 2011
• Last Verified: October 2011

Additional relevant MeSH terms:

Rhinitis; Rhinitis, Allergic; Respiratory Tract Infections; Infections; Nose Diseases; Respiratory Tract Diseases; Otorhinolaryngologic Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Diphenhydramine; Promethazine; Sleep Aids, Pharmaceutical; Hypnotics and Sedatives; Central Nervous System Depressants; Physiological Effects of Drugs; Anesthetics, Local; Anesthetics; Sensory System Agents; Peripheral Nervous System Agents; Antiemetics; Autonomic Agents; Gastrointestinal Agents; Histamine H1 Antagonists; Histamine Antagonists; Histamine Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Anti-Allergic Agents